详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Live-attenuated Japanese encephalitis virus inhibits glioblastoma growth and elicits potent antitumor immunity

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China. [2]Department of Biotherapy, Cancer Center, West China Hospital of Sichuan University, Chengdu, China. [3]Department of Arboviruses Vaccine, National Institute for Food and Drug Control, Beijing, China.

出处：

DOI：

关键词： glioblastoma oncolytic virotherapy anti-tumor immunity aPD-L1 live-attenuated Japanese encephalitis vaccine virus oncolytic virus

摘要：

Glioblastomas (GBMs) are highly aggressive brain tumors that have developed resistance to currently available conventional therapies, including surgery, radiation, and systemic chemotherapy. In this study, we investigated the safety of a live attenuated Japanese encephalitis vaccine strain (JEV-LAV) virus as an oncolytic virus for intracerebral injection in mice. We infected different GBM cell lines with JEV-LAV to investigate whether it had growth inhibitory effects on GBM cell lines in vitro. We used two models for evaluating the effect of JEV-LAV on GBM growth in mice. We investigated the antitumor immune mechanism of JEV-LAV through flow cytometry and immunohistochemistry. We explored the possibility of combining JEV-LAV with PD-L1 blocking therapy. This work suggested that JEV-LAV had oncolytic activity against GBM tumor cells in vitro and inhibited their growth in vivo. Mechanistically, JEV-LAV increased CD8+ T cell infiltration into tumor tissues and remodeled the immunosuppressive GBM microenvironment that is non-conducive to immunotherapy. Consequently, the results of combining JEV-LAV with immune checkpoint inhibitors indicated that JEV-LAV therapy improved the response of aPD-L1 blockade therapy against GBM. The safety of intracerebrally injected JEV-LAV in animals further supported the clinical use of JEV-LAV for GBM treatment.Copyright © 2023 Qi, Zhao, Li, Zhang, Hu, Chen, Ma, Shu, Wang and Cheng.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 2 区医学

小类 | 2 区免疫学

最新[2023]版：

大类 | 2 区医学

小类 | 2 区免疫学

第一作者：

第一作者机构： [1]State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China.

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]The emerging field of oncolytic virus-based cancer immunotherapy [2]Whole-cell tumor vaccines desialylated to uncover tumor antigenic Gal/GalNAc epitopes elicit anti-tumor immunity [3]小鼠肺癌B7疫苗细胞FLB2C诱导的抗肿瘤免疫应答 [4]Editorial: The impact of the DNA damage response on anti-tumor immunity [5]Necroptosis in tumorigenesis, activation of anti-tumor immunity, and cancer therapy. [6]Nanobody-Engineered Biohybrid Bacteria Targeting Gastrointestinal Cancers Induce Robust STING-Mediated Anti-Tumor Immunity [7]Metabolism-Related Prognostic Biomarkers, Purine Metabolism and Anti-Tumor Immunity in Colon Adenocarcinoma [8]Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity. [9]Advances in oncolytic herpes simplex virus and adenovirus therapy for recurrent glioma [10]Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma.